Clinical trial
ACTIV-2: A Study for Outpatients With COVID-19
NCT04518410 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT04518410 |
|---|---|
| Title | ACTIV-2: A Study for Outpatients With COVID-19 |
| Official title | Adaptive Platform Treatment Trial for Outpatients With COVID-19 (Adapt Out COVID) |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Eli Lilly and Company Industry Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections Brii Biosciences Limited AstraZeneca Sagent Pharmaceuticals Synairgen Research Ltd… |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Coronavirus, Covid19 |
| Intervention type | Biological, Drug |
| Interventions | bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV), AZD7442 (IM), SNG001, Camostat, BMS-986414 + BMS-986413, SAB-185 (3, 840 Units/kg), SAB-185 (10 and 13 more |
| Enrollment | 4,044 |
| Start date | Aug 19, 2020 |
| Primary completion | Apr 7, 2022 |
| Completion | Jun 20, 2023 |
| First posted | Aug 19, 2020 |
| Last update posted | Aug 2, 2024 |
| Countries | Argentina, Brazil, Canada, Guatemala, Mexico, Philippines, Puerto Rico, South Africa, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: